Background GLP-1 receptor agonists (GLP-1 RAs) with exenatide bid first approved to treat
type 2 diabetes in 2005 have been further developed to yield effective compounds …

Dipeptidyl peptidase 4 inhibitors (DPP4i) have been available for treating type 2 diabetes
mellitus since 2006. Although they are a diverse group, DPP4i are all small, orally available …

The discovery of glucagon-like peptide-1 (GLP-1), an incretin hormone with important effects
on glycemic control and body weight regulation, led to efforts to extend its half-life and make …

Type 2 diabetes mellitus is a risk factor for incident heart failure and increases the risk of
morbidity and mortality in patients with established disease. Secular trends in the …

Incretin hormones are gut peptides that are secreted after nutrient intake and stimulate
insulin secretion together with hyperglycaemia. GIP (glucose‐dependent insulinotropic …

Dipeptidyl peptidase-4 (DPP-4), also known as the T-cell antigen CD26, is a multi-functional
protein which, besides its catalytic activity, also functions as a binding protein and a ligand …

Liraglutide is an acylated glucagon-like peptide-1 (GLP-1) analogue that binds to serum
albumin in vivo and is approved for once-daily treatment of diabetes as well as obesity. The …

GLP-1, a peptide hormone secreted from the gut, stimulating insulin and suppressing
glucagon secretion was identified as a parent compound for novel treatments of diabetes …

Abstract Dipeptidyl peptidase-4 (DPP4) is a widely expressed enzyme transducing actions
through an anchored transmembrane molecule and a soluble circulating protein. Both …

In healthy humans, the incretin glucagon-like peptide 1 (GLP-1) is secreted after eating and
lowers glucose concentrations by augmenting insulin secretion and suppressing glucagon …